{"id":"NCT01218308","sponsor":"GlaxoSmithKline","briefTitle":"A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children","officialTitle":"Efficacy Study of GSK Biologicals' Quadrivalent Influenza Vaccine, GSK2282512A, (FLU Q-QIV) When Administered in Children","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-12-09","primaryCompletion":"2012-01-09","completion":"2012-01-09","firstPosted":"2010-10-11","resultsPosted":"2013-04-02","lastUpdate":"2018-08-01"},"enrollment":5220,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"FluLaval® Quadrivalent","otherNames":["Quadrivalent seasonal influenza vaccine GSK2282512A"]},{"type":"BIOLOGICAL","name":"Havrix™","otherNames":[]}],"arms":[{"label":"FluLaval® Quadrivalent Group","type":"EXPERIMENTAL"},{"label":"Havrix Group","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed to test the efficacy of an investigational influenza vaccine, in children compared to Havrix®, a licensed Hepatitis A virus vaccine.\n\nThis study will also evaluate the immunogenicity and safety of the investigational vaccine.","primaryOutcome":{"measure":"Number of Subjects Reporting at Least One Confirmed Occurrence of Influenza A or B.","timeFrame":"From Day 14 to Day 180","effectByArm":[{"arm":"FluLaval® Quadrivalent Group","deltaMin":58,"sd":null},{"arm":"Havrix Group","deltaMin":128,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":13},"locations":{"siteCount":12,"countries":["Bangladesh","Dominican Republic","Honduras","Lebanon","Panama","Philippines","Thailand","Turkey (Türkiye)"]},"refs":{"pmids":["24328444"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":2584},"commonTop":["Pain","Headache","Muscle aches","Nasopharyngitis","Fatigue"]}}